This website is intended for healthcare professionals only.

Newsletter          
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Approximately 1 in 3 women will develop uterine fibroids at some point in their life.1 Physical symptoms of uterine fibroids include pain, anaemia, heavy menstrual bleeding, and pelvic discomfort.2 Uterine fibroids also take a psychological toll; 95% of uterine fibroid patients experience psychological distress.3 Ryeqo is a novel gonadotropin-releasing hormone (GnRH) receptor antagonist combined with add-back therapy and is the first combination therapy licensed in the UK for the management of moderate to severe symptoms of uterine fibroids.4 Add-back therapy is a strategy of adding other medication during treatment with GnRH analogues with the aim to limit adverse events.5 Ryeqo is indicated for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.4 Prescribing information for Ryeqo can be found here. For more promotional information about Ryeqo, visit www.ryeqo.co.uk

New therapy for the management of moderate to severe symptoms of uterine fibroids

Watch Professor Ayman Al-Hendy discuss how a novel GnRH antagonist with add-back therapy can benefit patients with moderate to severe symptoms of uterine fibroids. The webinar also covered the results from the LIBERTY trials, the phase III development programme. This webinar was presented live on 27 June 2022.

The current management of women with uterine fibroids in the UK

Watch Professor Justin Clark discuss the current options for the management of women with uterine fibroids in the UK. This webinar was presented live on 27 June 2022.

COMING SOON

Cause and Impact of Uterine Fibroids (UF)

Introducing the incidence and symptoms of UFs, focusing on their impact on patient quality of life (QoL).

Ryeqo Mode of Action

RYEQO is a GnRH antagonist (relugolix) combined with estradiol and norethisterone acetate Relugolix’s pharmacological inhibition of the GnRH receptors within the body causes a reduction in the production of estradiol, creating an environment that does not support the growth of fibroids.

Professor Ayman Al-Hendy, MD PhD FRCSC FACOG CCRP 

Professor Al-Hendy is the Director of Translational Research from the Department of Obstetrics and Gynecology at the University of Illinois (Chicago, USA). He is the first author of the clinical studies covered in this webinar. 

Professor Justin Clark

Professor Clark is a Consultant Gynaecologist at the Birmingham Women’s Hospital and an Honorary Professor at the University of Birmingham. Member of the Royal College of Obstetrics and Gynaecology (MRCOG) and Fellow of the Royal College (FRCOG). 

Adverse events should be reported. Reporting forms and information can be found at: https://www.yellowcard.mhra.gov.uk or you can report via the Yellow Card app which is available to download from the Apple App Store or Google Play Store. Adverse events should also be reported to Gedeon Richter (UK) Ltd on +44 (0) 207 604 8806 or by email to [email protected].

References

  1. NHS. Fibroids. Available at https://www.nhs.uk/conditions/fibroids/ (accessed February 2022)
  2. Al-Hendy A et al. Semin Reprod Med 2017;35:473–480
  3. Ghant MS et al. J Psychosom Res 2015;78:499–503
  4. Ryeqo Summary of product characteristics
  5. Moroni RM et al. Cochrane Database Syst Rev 2015:CD010854
Date of prep: June 2022
Job Code: UK-RYQ-2200060